Asia Pacific Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)
The Asia Pacific monoclonal antibodies market is expected to reach US$ 44,729.7 million by 2028 from US$ 18,344.5 million in 2021. The market is estimated to grow at a CAGR of 13.6% from 2021–2028.
Advancements in manufacturing technologies with packaging and delivery can lower mAB production costs and increase efficiency. For example, WHO policy guidelines play an important role in adopting new technologies and their integration in financing and procurement platforms. Therefore, novel technologies are expected to lower mAB development and manufacturing costs during the forecast period. For instance, the IAVI report states that many researchers are applying cost-effective technologies for optimizing HIV-specific bnmABs for increasing potency, thereby lowering the cost of the overall product. Additionally, recent technological advancements offer lucrative opportunities to quickly isolate, develop and produce therapeutic or preventative mABs as a complementary approach to vaccine development as part of preparing for or responding to current and future pandemic outbreaks. For example, incorporating technological advancements in the process of identifying, optimizing, and producing results in delivering more potent, lower-cost monoclonal antibody products. Together, such strategic actions are expected to make it possible to address the growing inequity to these products, saving or improving millions of lives in the process in the near future. Therefore, with the influx of advanced technology for the development of mABs, the mAB market will grow faster in the coming years. For example, as per the statistics released by Firestone, approx. 43% of mAB sales were intended to treat immune system diseases, while 35% were used for tumor therapy in 2015. The sales of mABs accounted for over half of the total sales of all biopharmaceutical products.The supply chain disruptions, along with the massive demand for efficient treatments for the therapy of COVID-19, have put the healthcare research industry in a crucial situation in the Asia Pacific region. Prohibitive measures have been taken to control the spread of this pandemic. COVID-19 pandemic has broadly affected that economies in the Asia Pacific region. Countries such as India, China, Japan, South Korea were adversely affected by the pandemic. The socio-economics were severely affected, rising in negative inflation, GDPs, and a surge in unemployment in the region. The pandemic has affected three main aspects of the global economy: production, supply chain, and firms and financial markets. Japan, China, South Korea, India, and Australia are the most affected countries due to the increasing number of COVID-19 cases and the associated deaths. Manufacturers and suppliers of pharmaceuticals shift their focus from regular OTC and prescription drugs to developing and supplying COVID-19 essentials and medical devices used for respiratory issues. This scenario negatively impacts the monoclonal antibody. This pandemic is affecting the business operation of the various key players operating in this region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Asia Pacific monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.
Asia Pacific Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
Asia Pacific Monoclonal Antibodies Market Segmentation
By Source
- Human
- Humanized
- Chimeric
- Murine
By Production Method
- In-Vitro
- In-Vivo
By Indication
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Inflammatory Diseases
- Microbial Diseases
- Others
By Application
- Therapeutic Applications
- Diagnostic Applications
- Research Applications
By End-User
- Hospitals
- Research Institutes
- Others
By Country
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
Companies Mentioned
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc.
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Eli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Monoclonal Antibodies (mAbs) Market – By Source
1.3.2 Asia Pacific Monoclonal Antibodies (mAbs) Market – By Production Method
1.3.3 Asia Pacific Monoclonal Antibodies (mAbs) Market – By Indication
1.3.4 Asia Pacific Monoclonal Antibodies (mAbs) Market – By Application
1.3.5 Asia Pacific Monoclonal Antibodies (mAbs) Market – By End-User
1.3.6 Asia Pacific Monoclonal Antibodies (mAbs) Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Monoclonal Antibodies (mAbs) Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific PEST Analysis
4.3 Experts Opinion
5. Monoclonal Antibodies (mAbs) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Cancer and Other Chronic Diseases
5.1.2 mABs Uptake Proves to be Effective During Pandemic Outbreak
5.2 Market Restraints
5.2.1 Low Awareness, Accessibility, and High Cost
5.3 Market Opportunities
5.3.1 Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity
5.4 Future Trends
5.4.1 Strategic Research Collaborations
5.5 Impact Analysis
6. Monoclonal Antibodies (mAbs) Market– Asia Pacific Analysis
6.1 Asia Pacific Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis
7. Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source
7.1 Overview
7.2 Asia Pacific Monoclonal Antibodies (mAbs) Market, By Source, 2020 & 2028 (%)
7.3 Murine
7.3.1 Overview
7.3.2 Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Chimeric
7.4.1 Overview
7.4.2 Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.5 Humanized
7.5.1 Overview
7.5.2 Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
7.6 Human
7.6.1 Overview
7.6.2 Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
8. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method
8.1 Overview
8.2 Asia Pacific Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)
8.3 In-Vivo
8.3.1 Overview
8.3.2 In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
8.4 In-Vitro
8.4.1 Overview
8.4.2 In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication
9.1 Overview
9.2 Asia Pacific Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)
9.3 Cancer
9.3.1 Overview
9.3.2 Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.5 Inflammatory Diseases
9.5.1 Overview
9.5.2 Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.6 Infectious Diseases
9.6.1 Overview
9.6.2 Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.7 Microbial Diseases
9.7.1 Overview
9.7.2 Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application
10.1 Overview
10.2 Asia Pacific Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)
10.3 Diagnostic Applications
10.3.1 Overview
10.3.2 Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.4 Therapeutic Applications
10.4.1 Overview
10.4.2 Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
10.5 Research Applications
10.5.1 Overview
10.5.2 Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User
11.1 Overview
11.2 Asia Pacific Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)
11.3 Hospitals
11.3.1 Overview
11.3.2 Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.4 Research Institutes
11.4.1 Overview
11.4.2 Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)
12. Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis
12.1 Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028
12.1.1 Overview
12.1.2 Asia Pacific: Monoclonal Antibodies (mAbs) Market - Revenue and Forecast to 2028 (USD Million)
12.1.3 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.4 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)
12.1.5 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)
12.1.6 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)
12.1.7 Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
12.1.8 Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Country, 2021 & 2028 (%)
12.1.8.1 China: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.1.1 China: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.1.2 China: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.8.1.3 China: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)
12.1.8.1.4 China: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)
12.1.8.1.5 China: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)
12.1.8.1.6 China: Monoclonal Antibodies (mAbs) Market, by Product, 2019–2028 (USD Million)
12.1.8.1.7 China: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
12.1.8.2 Japan: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.2.1 Japan: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.2.2 Japan: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.8.2.3 Japan: Monoclonal Antibodies (mAbs) Market, by Product, 2019–2028 (USD Million)
12.1.8.2.4 Japan: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)
12.1.8.2.5 Japan: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)
12.1.8.2.6 Japan: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)
12.1.8.2.7 Japan: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
12.1.8.3 India: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.3.1 India: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.3.2 India: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.8.3.3 India: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)
12.1.8.3.4 India: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)
12.1.8.3.5 India: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)
12.1.8.3.6 India: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
12.1.8.4 South Korea: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.4.1 South Korea: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.4.2 South Korea: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.8.4.3 South Korea: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)
12.1.8.4.4 South Korea: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)
12.1.8.4.5 South Korea: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
12.1.8.5 Australia: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.5.1 Australia: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.5.2 Australia: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.8.5.3 Australia: Monoclonal Antibodies (mAbs) Market, By Production Method, 2019–2028 (USD Million)
12.1.8.5.4 Australia: Monoclonal Antibodies (mAbs) Market, By Indication, 2019–2028 (USD Million)
12.1.8.5.5 Australia: Monoclonal Antibodies (mAbs) Market, By Application, 2019–2028 (USD Million)
12.1.8.5.6 Australia: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
12.1.8.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.6.1 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market – Revenue and Forecast to 2028 (USD Million)
12.1.8.6.2 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Source, 2019–2028 (USD Million)
12.1.8.6.3 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Production Method, 2019–2028 (USD Million)
12.1.8.6.4 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Indication, 2019–2028 (USD Million)
12.1.8.6.5 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Application, 2019–2028 (USD Million)
12.1.8.6.6 Rest of Asia Pacific: Monoclonal Antibodies (mAbs) Market, By End User, 2019–2028 (USD Million)
13. Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market
13.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
14. Monoclonal Antibodies (mAbs) Market–Industry Landscape
14.1 Overview
14.2 Growth Strategies Done by the Companies in the Market, (%)
14.3 Organic Developments
14.3.1 Overview
14.4 Inorganic Developments
14.4.1 Overview
15. Company Profiles
15.1 Novartis AG
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Pfizer Inc.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 GlaxoSmithKline plc.
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Amgen Inc.
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 DAIICHI SANKYO COMPANY LIMITED
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 F. HOFFMANN-LA ROCHE LTD.
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 AstraZeneca
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Eli Lilly and Company.
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Bayer AG
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Bristol-Myers Squibb Company
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 2. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)
Table 3. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 4. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 5. Asia Pacific Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 6. China Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 7. China Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)
Table 8. China Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 9. China Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 10. China Monoclonal Antibodies (mAbs) Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 11. China Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 12. Japan Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 13. Japan Monoclonal Antibodies (mAbs) Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 14. Japan Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)
Table 15. Japan Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 16. Japan Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 17. Japan Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 18. India Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 19. India Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)
Table 20. India Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 21. India Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 22. India Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 23. South Korea Monoclonal Antibodies (mAbs) Market, by Product – Revenue and Forecast to 2028 (USD Million)
Table 24. South Korea Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)
Table 25. South Korea Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 26. South Korea Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 27. Australia Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 28. Australia Monoclonal Antibodies (mAbs) Market, By Production Method – Revenue and Forecast to 2028 (USD Million)
Table 29. Australia Monoclonal Antibodies (mAbs) Market, By Indication – Revenue and Forecast to 2028 (USD Million)
Table 30. Australia Monoclonal Antibodies (mAbs) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 31. Australia Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 32. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source – Revenue and Forecast to 2028 (USD Million)
Table 33. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Production Method – Revenue and Forecast to 2028 (USD Million)
Table 34. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (USD Million)
Table 35. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 36. Rest of Asia Pacific Monoclonal Antibodies (mAbs) Market, By End User – Revenue and Forecast to 2028 (USD Million)
Table 37. Organic Developments Done by Companies
Table 38. Inorganic Developments Done by Companies
Table 39. Glossary of Terms
LIST OF FIGURES
Figure 1. Monoclonal Antibodies (mAbs) Market Segmentation
Figure 2. Asia Pacific Monoclonal Antibodies (mAbs) Market Overview
Figure 3. Human Segment Held Largest Share of Source Segment in Monoclonal Antibodies (mAbs) Market
Figure 4. China is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Asia Pacific Monoclonal Antibodies (mAbs) Market, Industry Landscape
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market
Figure 9. Asia Pacific Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028
Figure 10. Asia Pacific Monoclonal Antibodies (mAbs) Market, by Source, 2020 & 2028 (%)
Figure 11. Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Asia Pacific Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)
Figure 16. In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. Asia Pacific Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)
Figure 19. Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Asia Pacific Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)
Figure 26. Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 27. Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. Asia Pacific Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)
Figure 30. Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. Asia Pacific: Monoclonal Antibodies (mAbs) Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. Asia Pacific Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (USD Million)
Figure 35. Impact of COVID-19 Pandemic in Asia Pacific Country Markets
Figure 36. Growth Strategies Done by the Companies in the Market, (%)
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc.
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- F. Hoffmann-La Roche Ltd.
- AstraZeneca
- Eli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific monoclonal antibodies market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.